Botanix Reports 16,000 Prescriptions and $25M Sales Since January

Botanix Sales and Prescription Growth Confirmed

Botanix Pharmaceuticals Limited has formally responded to an ASX Aware Letter concerning the materiality and timing of its recent disclosures. The company confirmed that gross sales have reached approximately AUD 25 million since January 2025, with consistent month-over-month growth through June. Additionally, Botanix reported over 16,000 prescriptions filled across 6,700 patients since launch, underscoring steady market uptake of its products.

High Patient Adherence Rates Highlighted

Significantly, Botanix highlighted a 95% adherence rate among patients enrolled in its auto-refill program, compared to a 79% adherence rate across all patients. This metric is a key indicator of patient engagement and treatment continuity, factors that can influence long-term sales and clinical outcomes.

Disclosure Timing and ASX Compliance

The company explained that the delay in releasing this information was due to the necessary reconciliation of preliminary sales and prescription data against inventory counts, followed by thorough quality checks. This process extended over two weeks, with final data verification completed by 4 July 2025 and management approval by 7 July. The announcement was then promptly released to the market on 8 July 2025.

Botanix affirmed its compliance with ASX Listing Rules 3.1 and 3.1A, which govern continuous disclosure obligations. The company stated that it was not obliged to release the information earlier, given the time required to ensure data accuracy and completeness.

Market Reaction and Next Steps

Following the announcement, Botanix’s share price experienced volatility, dropping from a close of $0.31 on 7 July to an intraday low of $0.13 on 8 July. While the company’s disclosures clarified the material nature of the sales and prescription data, the market’s reaction suggests investors are digesting the implications amid broader sector dynamics.

Looking ahead, Botanix’s ability to sustain sales growth and maintain high patient adherence will be critical metrics for investors. The company’s transparent communication with ASX and adherence to disclosure protocols will also remain under close watch.